Literature DB >> 22688585

Prognostic value of histological grading in noninflammatory canine mammary carcinomas in a prospective study with two-year follow-up: relationship with clinical and histological characteristics.

L Peña1, P J De Andrés, M Clemente, P Cuesta, M D Pérez-Alenza.   

Abstract

In this prospective study, a canine-adapted histological grading method was compared with histopathological and clinical characteristics and was evaluated as a prognostic indicator in canine mammary carcinomas (CMCs). Recruited dogs with at least 1 malignant mammary tumor (n = 65) were clinically evaluated, surgically treated, and followed up (minimum follow-up 28 months, maximum 38 months). Histopathological diagnoses were performed according to Goldschmidt et al (2011). Tumors were graded as grade I (29/65), grade II (19/65), and grade III (17/65). The tumor size, clinical stage, histological diagnosis, presence/absence of myoepithelial proliferation, and regional lymph node metastases at diagnosis were significantly associated with histological grade. The histological grade, age, clinical stage, tumor subtype group, and lymph node metastases at time of diagnosis were significantly associated with the development of recurrences and/or metastases, cancer-associated death, and survival times (disease-free survival and overall survival) in univariate analyses. A subdivision of clinical stage I (T1N0M0) into stages IA and IB was proposed in terms of prognosis. The clinical stage, histological grade, and spay status were selected as independent prognostic variables (multivariate analyses) with disease-free survival as the dependent variable. When overall survival was evaluated as a dependent variable, clinical stage and histological grade were selected as the independent covariates. This grading system is a useful prognostic tool, facilitates histological interpretation, and offers uniform criteria for veterinary pathologists. Comparative studies on CMCs performed in different countries should take into account possible changes in the prognoses due to different proportions of spayed females among the selected dog population.

Entities:  

Mesh:

Year:  2012        PMID: 22688585     DOI: 10.1177/0300985812447830

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  39 in total

1.  Clinical staging in bitches with mammary tumors: Influence of type and histological grade.

Authors:  Lígia F Gundim; Camila P de Araújo; William T Blanca; Ednaldo C Guimarães; Alessandra A Medeiros
Journal:  Can J Vet Res       Date:  2016-10       Impact factor: 1.310

2.  MicroRNA-21 expression, serum tumor markers, and immunohistochemistry in canine mammary tumors.

Authors:  Eman S Ramadan; Noha Y Salem; Ibrahim A Emam; Naglaa A AbdElKader; Haithem A Farghali; Marwa S Khattab
Journal:  Vet Res Commun       Date:  2021-11-17       Impact factor: 2.459

3.  Validation of AmpliSeq NGS Panel for BRCA1 and BRCA2 Variant Detection in Canine Formalin-Fixed Paraffin-Embedded Mammary Tumors.

Authors:  Daniela Di Giacomo; Marco Di Domenico; Sabrina Vanessa Patrizia Defourny; Daniela Malatesta; Giovanni Di Teodoro; Michele Martino; Antonello Viola; Nicola D'Alterio; Cesare Cammà; Paola Modesto; Antonio Petrini
Journal:  Life (Basel)       Date:  2022-06-07

4.  Breed- and age-related differences in canine mammary tumors.

Authors:  Hyun-Woo Kim; Ha-Young Lim; Jong-Il Shin; Byung-Joon Seung; Jung-Hyung Ju; Jung-Hyang Sur
Journal:  Can J Vet Res       Date:  2016-04       Impact factor: 1.310

5.  Vitamin D receptor (VDR) expression in different molecular subtypes of canine mammary carcinoma.

Authors:  R Sánchez-Céspedes; M D Fernández-Martínez; A I Raya; C Pineda; I López; Y Millán
Journal:  BMC Vet Res       Date:  2021-05-25       Impact factor: 2.741

6.  Canine Mammary Tumours Are Affected by Frequent Copy Number Aberrations, including Amplification of MYC and Loss of PTEN.

Authors:  Kaja S Borge; Silje Nord; Peter Van Loo; Ole C Lingjærde; Gjermund Gunnes; Grethe I G Alnæs; Hiroko K Solvang; Torben Lüders; Vessela N Kristensen; Anne-Lise Børresen-Dale; Frode Lingaas
Journal:  PLoS One       Date:  2015-05-08       Impact factor: 3.240

7.  Effect of Ovariohysterectomy at the Time of Tumor Removal in Dogs with Mammary Carcinomas: A Randomized Controlled Trial.

Authors:  V M Kristiansen; L Peña; L Díez Córdova; J C Illera; E Skjerve; A M Breen; M A Cofone; M Langeland; J Teige; M Goldschmidt; K U Sørenmo
Journal:  J Vet Intern Med       Date:  2015-12-21       Impact factor: 3.333

8.  Circulating Cell-Free DNA in Dogs with Mammary Tumors: Short and Long Fragments and Integrity Index.

Authors:  Giorgia Beffagna; Alessandro Sammarco; Chiara Bedin; Chiara Romualdi; Marta Mainenti; Antonio Mollo; Laura Cavicchioli; Silvia Ferro; Davide Trez; Raffaella De Maria; Donato Nitti; Andrea Saccani; Michelangelo Campanella; Marco Agostini; Valentina Zappulli
Journal:  PLoS One       Date:  2017-01-12       Impact factor: 3.240

9.  Effects of Lapatinib on HER2-Positive and HER2-Negative Canine Mammary Carcinoma Cells Cultured In Vitro.

Authors:  Antonio Fernando Leis-Filho; Patrícia de Faria Lainetti; Priscila Emiko Kobayashi; Carlos Eduardo Fonseca-Alves; Renée Laufer-Amorim
Journal:  Pharmaceutics       Date:  2021-06-17       Impact factor: 6.321

10.  Gene expression profiles in canine mammary carcinomas of various grades of malignancy.

Authors:  Karol M Pawłowski; Henryk Maciejewski; Izabella Dolka; Jan A Mol; Tomasz Motyl; Magdalena Król
Journal:  BMC Vet Res       Date:  2013-04-15       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.